Conatumumab

Generic Name: AMG 655
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20050171Advanced, treatment-refractory tumors1A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 655 in Subjects with Advanced Tumors.
20060295Stage IIIb/IV non-small cell lung cancer1b/2A Phase 1b/2 Study of AMG 655 in Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
20060323Metastatic adenocarcinoma of the pancreas1b/2A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AMG 655 or AMG 479 in Combination with Gemcitabine as First-line Therapy for Metastatic Pancreatic Cancer
20060324Soft tissue sarcoma (locally advanced or metastatic, unresectable)1b/2A Phase 1b/2 Study of AMG 655 in Combination With Doxorubicin for the First-Line Treatment of Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma
20060340Relapsed or refractory lymphoma (Part 1); mantle cell lymphoma (Part 2)1bA Phase 1b Study to Evaluate the Safety and Tolerability of AMG 655 in Combination with Bortezomib or Vorinostat in Subjects with Relapsed or Refractory Lymphoma
20060464Stage IV colorectal cancer1b/2A Phase 1b/2 Study of AMG 655 in Combination With Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects With Metastatic Colorectal Cancer
20060579Second-line treatment of KRAS mutant-type metastatic colorectal cancer2A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
20070411Advanced, treatment-refractory solid tumors1b/2A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors